NCT00720629 · OUTCOME

Incidence of Epstein-Barr Virus (EBV) Reactivation

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation · Source last updated 2014-07-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: 3 months

What was measured

Number of participants who reactivated EBV. Patients had their plasma tested once weekly using the TaqMan polymerase chain reaction (PCR) for quantitative determination of EBV-DNA for 6 weeks. Plasma levels \> 1000 copies per ml plasma were scored as positive.

Analysis population: All participants

Groups in this outcome

First Study Stage: Study Treatment

Visilizumab, Tacrolimus and Methotrexate. All participants.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
First Study Stage: Study Treatment	8

Reported measurements

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
First Study Stage: Study Treatment	6	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
6

denoms

counts
group Id
OG000
value
8
units
Participants

description

groups

description
Visilizumab, Tacrolimus and Methotrexate. All participants.
id
OG000
title
First Study Stage: Study Treatment

param Type

NUMBER

population Description

All participants

reporting Status

POSTED

time Frame

3 months

title

Incidence of Epstein-Barr Virus (EBV) Reactivation

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice